C.M. Bidwell & Associates’s Haemonetics HAE Stock Holding History

C.M. Bidwell & Associates’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-478	Closed	-$38.4K	–	509
2024 Q3	$38.4K	Sell	478 -509	-52%	-$41.1K	0.02%	238
2024 Q2	$81.7K	Hold	987	–	–	0.05%	196
2024 Q1	$84.2K	Buy	987 +189	+24%	+$14.8K	0.06%	195
2023 Q4	$68.2K	Sell	798 -1,591	-67%	-$138K	0.05%	198
2023 Q3	$214K	Buy	2,389 +393	+20%	+$35.1K	0.16%	105
2023 Q2	$170K	Hold	1,996	–	–	0.12%	144
2023 Q1	$165K	Buy	+1,996	New	+$162K	0.13%	142
2019 Q1	–	Sell	-750	Closed	-$75K	–	430
2018 Q4	$75K	Sell	750 -170	-18%	-$17.9K	0.08%	210
2018 Q3	$105K	Sell	920 -165	-15%	-$17.1K	0.1%	186
2018 Q2	$97K	Sell	1,085 -15	-1%	-$1.27K	0.09%	188
2018 Q1	$80K	Buy	+1,100	New	+$75.5K	0.07%	211

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

C.M. Bidwell & Associates's HAE Position: Q4 2024 in Review

C.M. Bidwell & Associates sold out of Haemonetics (HAE) in Q4 2024, closing a stake of 478 shares — an estimated $38.4K sold.

C.M. Bidwell & Associates first reported a position in HAE in Q1 2018 and held it in 11 quarters. The position peaked at $214K in Q3 2023. 309 funds tracked by Wall St. Rank hold HAE as of Q4 2024.

C.M. Bidwell & Associates reported no remaining Haemonetics position as of Q4 2024 after selling out during the quarter.
C.M. Bidwell & Associates sold 478 Haemonetics shares in Q4 2024, an estimated $38.4K.
C.M. Bidwell & Associates first reported a position in Haemonetics in Q1 2018 and held it in 11 quarters.
C.M. Bidwell & Associates's Haemonetics position peaked at $214K in Q3 2023.
309 funds tracked by Wall St. Rank held Haemonetics as of Q4 2024.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2024, filed 12 Feb 2025.